All in-house stories
Regulation & Industry
Blockbuster acquisitions are back, impacting the pharma industry at record pace. As billions flow into breakthrough science, LSIPR’s series explores what’s driving the surge, how today’s deals are done, and where IP comes into the picture. 17 July 2026
Careers
Kevin Scott will lead the organisation representing in-house counsel in the UK, for companies such as AstraZeneca, Eli Lilly, MSD and Regeneron. 14 July 2026
In-house counsel
The company’s VP of IP explains how he is protecting the process, staying ahead of outside counsel, and why a biosimilar path is only a matter of time. 13 July 2026
Biotech
Harbour’s trial counsel shares the strategy behind the company’s $20m win, revealing how a highly technical patent dispute became a case about credibility as much as science. 10 July 2026
Careers
The firm has appointed two new partners in Basel and Bristol, adding decades of expertise from the pharmaceutical and biotech sectors to its growing life sciences practice. 2 July 2026
Pharma
Otsuka v Sun Pharma could redefine which pharmaceutical patents qualify for patent term extensions, with major implications for innovator companies, generic manufacturers and the future of market exclusivity in the country. 1 July 2026
Regulation & Industry
Despite a slowdown in US patent litigation, life sciences remains one of the most active sectors—but companies are using a wider than ever IP toolkit, says a new study. 18 June 2026
Pharma
The Supreme Court's first look at the skinny label dispute dug into key questions, from the role of the skinny label to who Hikma’s statements were really meant for, in one of the most important patent cases in years. 30 April 2026